XM does not provide services to residents of the United States of America.

Japan's Nikkei rises as chip-related shares track Nvidia higher



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>Japan's Nikkei rises as chip-related shares track Nvidia higher</title></head><body>

TOKYO, Nov 22 (Reuters) -Japan's Nikkei share average rose on Friday after two straight sessions of falls, as chip-related stocks tracked artificial intelligence darling Nvidia higher.

The Nikkei .N225 had gained 1.02% to 38,415.32 by the midday break, but was set to fall 1.6% for the week.

The broader Topix .TOPX rose 0.8% to 2,704.34, but was poised for a 1% weekly loss.

"Nvidia's gains lifted sentiment and investors bought back Japanese stocks," said Naoki Fujiwara, senior general manager at Shinkin Asset Management.

"And it was time for making active bets after the Nikkei fell below 38,000 in the previous session."

The Nikkei index hit a low of 37,945.21 in intraday trade on Thursday, falling below 38,000 for the first time since Nov. 1. The index closed at its lowest since Oct. 25.

Wall Street's main indexes closed higher after a choppy session on Thursday, with the blue-chip Dow and the S&P 500 hitting one-week tops. .N

Shares of Wall Street's biggest company, Nvidia NVDA.O, climbed 0.5% after teetering following the earnings release on Wednesday. The U.S. semiconductor index .SOX rose 1.6%.

In Japan, chip-making equipment maker Tokyo Electron 8035.T jumped 2.5%. Chip-testing equipment maker Advantest 6857.T rose 1.78%. Chip materials maker Resonac 4004.T jumped 3.84%.

All but three of the Tokyo Stock Exchange's 33 industry sub-indexes rose, with refiners .IPETE.T rising 3.25% to become the top performer.

The drug sector .IPHAM.T slipped 0.1% and was the worst performer, with Daiichi Sankyo 4568.T falling 0.94% to weigh the most on the Topix. Chugai Pharmaceutical 4519.T lost 0.91%.

Of the 225 stocks on the Nikkei, 172 rose and 50 fell, with three trading flat.




Reporting by Junko Fujita; Editing by Subhranshu Sahu

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.